441 related articles for article (PubMed ID: 31678382)
41. Three-Dimensional (3D)-Printed Zero-Order Released Platform: a Novel Method of Personalized Dosage Form Design and Manufacturing.
Fang D; Yang Y; Cui M; Pan H; Wang L; Li P; Wu W; Qiao S; Pan W
AAPS PharmSciTech; 2021 Jan; 22(1):37. PubMed ID: 33409925
[TBL] [Abstract][Full Text] [Related]
42. The preparation of orally disintegrating tablets using a hydrophilic waxy binder.
Abdelbary G; Prinderre P; Eouani C; Joachim J; Reynier JP; Piccerelle P
Int J Pharm; 2004 Jul; 278(2):423-33. PubMed ID: 15196646
[TBL] [Abstract][Full Text] [Related]
43. Selective laser sintering (SLS) 3D printing of medicines.
Fina F; Goyanes A; Gaisford S; Basit AW
Int J Pharm; 2017 Aug; 529(1-2):285-293. PubMed ID: 28668582
[TBL] [Abstract][Full Text] [Related]
44. Development of an osmotic pump system for controlled delivery of diclofenac sodium.
Emara LH; Taha NF; Badr RM; Mursi NM
Drug Discov Ther; 2012 Oct; 6(5):269-77. PubMed ID: 23229148
[TBL] [Abstract][Full Text] [Related]
45. Chitosan and sodium sulfate as excipients in the preparation of prolonged release theophylline tablets.
Alsarra IA; El-Bagory I; Bayomi MA
Drug Dev Ind Pharm; 2005 May; 31(4-5):385-95. PubMed ID: 16093204
[TBL] [Abstract][Full Text] [Related]
46. Combination of 3D printing technologies and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems.
Fu J; Yin H; Yu X; Xie C; Jiang H; Jin Y; Sheng F
Int J Pharm; 2018 Oct; 549(1-2):370-379. PubMed ID: 30107218
[TBL] [Abstract][Full Text] [Related]
47. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing.
Alhijjaj M; Belton P; Qi S
Eur J Pharm Biopharm; 2016 Nov; 108():111-125. PubMed ID: 27594210
[TBL] [Abstract][Full Text] [Related]
48. Melt extrusion deposition (MED™) 3D printing technology - A paradigm shift in design and development of modified release drug products.
Zheng Y; Deng F; Wang B; Wu Y; Luo Q; Zuo X; Liu X; Cao L; Li M; Lu H; Cheng S; Li X
Int J Pharm; 2021 Jun; 602():120639. PubMed ID: 33901601
[TBL] [Abstract][Full Text] [Related]
49. Formulation and development of pH-independent/dependent sustained release matrix tablets of ondansetron HCl by a continuous twin-screw melt granulation process.
Patil H; Tiwari RV; Upadhye SB; Vladyka RS; Repka MA
Int J Pharm; 2015 Dec; 496(1):33-41. PubMed ID: 25863118
[TBL] [Abstract][Full Text] [Related]
50. Statistical moments in modelling of swelling, erosion and drug release of hydrophilic matrix-tablets.
Barmpalexis P; Kachrimanis K; Malamataris S
Int J Pharm; 2018 Apr; 540(1-2):1-10. PubMed ID: 29407874
[TBL] [Abstract][Full Text] [Related]
51. Continuous direct tablet compression: effects of impeller rotation rate, total feed rate and drug content on the tablet properties and drug release.
Järvinen MA; Paaso J; Paavola M; Leiviskä K; Juuti M; Muzzio F; Järvinen K
Drug Dev Ind Pharm; 2013 Nov; 39(11):1802-8. PubMed ID: 23163644
[TBL] [Abstract][Full Text] [Related]
52. A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets.
Okwuosa TC; Stefaniak D; Arafat B; Isreb A; Wan KW; Alhnan MA
Pharm Res; 2016 Nov; 33(11):2704-12. PubMed ID: 27506424
[TBL] [Abstract][Full Text] [Related]
53. Alginate-magnesium aluminum silicate films: effect of plasticizers on film properties, drug permeation and drug release from coated tablets.
Pongjanyakul T; Puttipipatkhachorn S
Int J Pharm; 2007 Mar; 333(1-2):34-44. PubMed ID: 17056214
[TBL] [Abstract][Full Text] [Related]
54. Controlled release matrix tablets of glipizide: Influence of different grades of ethocel and Co-excipient on drug release.
Mehsud SU; Khan GM; Hussain A; Akram M; Akhlaq M; Khan KA; Shakoor A
Pak J Pharm Sci; 2016 May; 29(3):779-87. PubMed ID: 27166548
[TBL] [Abstract][Full Text] [Related]
55. Development of sustained and dual drug release co-extrusion formulations for individual dosing.
Laukamp EJ; Vynckier AK; Voorspoels J; Thommes M; Breitkreutz J
Eur J Pharm Biopharm; 2015 Jan; 89():357-64. PubMed ID: 25555454
[TBL] [Abstract][Full Text] [Related]
56. Dissolution rate enhancement of parabens in PEG solid dispersions and its influence on the release from hydrophilic matrix tablets.
Tajarobi F; Abrahmsén-Alami S; Larsson A
J Pharm Sci; 2011 Jan; 100(1):275-83. PubMed ID: 20572053
[TBL] [Abstract][Full Text] [Related]
57. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets.
Li H; Hardy RJ; Gu X
AAPS PharmSciTech; 2008; 9(2):437-43. PubMed ID: 18431663
[TBL] [Abstract][Full Text] [Related]
58. Oral drug delivery systems using core-shell structure additive manufacturing technologies: a proof-of-concept study.
Zhang J; Xu P; Vo AQ; Repka MA
J Pharm Pharmacol; 2021 Mar; 73(2):152-160. PubMed ID: 33793804
[TBL] [Abstract][Full Text] [Related]
59. Release mechanisms of acetaminophen from polyethylene oxide/polyethylene glycol matrix tablets utilizing magnetic resonance imaging.
Tajiri T; Morita S; Sakamoto R; Suzuki M; Yamanashi S; Ozaki Y; Kitamura S
Int J Pharm; 2010 Aug; 395(1-2):147-53. PubMed ID: 20580795
[TBL] [Abstract][Full Text] [Related]
60. Design and Evaluation of Hydrophilic Matrix System Containing Polyethylene Oxides for the Zero-Order Controlled Delivery of Water-Insoluble Drugs.
Wang L; Chen K; Wen H; Ouyang D; Li X; Gao Y; Pan W; Yang X
AAPS PharmSciTech; 2017 Jan; 18(1):82-92. PubMed ID: 26883263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
